The size of the Asia Pacific Apheresis Market was worth USD 0.37 billion in 2024 and estimated to be growing at a CAGR of 12.58%, to reach USD 0.67 billion by 2029.
Apheresis is a medical procedure that involves the purifying of blood or the separation of distinct blood components. Separation of the component was accomplished using two methods like centrifugation and filtration. The presence of modern blood collection facilities, a strong presence of blood collection centers, significant product penetration, and high awareness among persons regarding blood component donation are all factors that contribute to Asia Pacific's success. In addition, the Asia Pacific area market is being driven by a growing end-user base, a growing population, and an increase in the prevalence of blood disorders.
The rising prevalence of chronic diseases and the increasing number of trauma and injury cases, the growing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns about blood safety, the rise in the number of complex surgical procedures, and favorable reimbursement for apheresis procedures are primarily accelerating the apheresis market growth in the APAC region.
In addition, the development of innovative apheresis techniques and the rising prevalence of various chronic diseases, blood-related diseases, and other diseases are driving the apheresis market. Increased demand for various blood components, increasing complexity of surgical operations, and an increase in the number of accidents across the Asia Pacific are expected to contribute to the market's rise during the forecast period. Private blood collection centers, which recruit donors through paid plans, combat a lack of regular blood donors. In recent years, hospitals have increased their use of apheresis equipment to collect and store essential blood components, reducing their reliance on private blood suppliers and collection centers.
The increase of platelet donors and biopharmaceutical companies R&D investments are expected to have a significant influence. In addition, the rising prevalence of blood-related illnesses is expected to drive up demand for apheresis devices and kits. Furthermore, favorable government measures and a recovery framework are expected to boost demand over the forecast period.
According to the National Health Service (NHS) Blood and Transplant, the need for platelets is increasing. While a shortage of qualified professionals and the ease with which blood and blood products can be infected, the risk of infection also contributes to the market's slow growth. However, the expensive cost of apheresis devices and therapeutic apheresis procedures, as well as the rental model's installation of apheresis machines, may limit market expansion. In addition, fewer blood donations using apheresis due to a lack of awareness and strict donor recruitment criteria are factors that are likely to stifle market growth and limit it to some extent in the coming years.
Geographically, the Asia Pacific is one of the most lucrative markets for the growth of the Apheresis market and is projected to grow the highest during the forecast period. Factors such as the growing prevalence of blood disorders requiring plasma and platelet transfusion, increasing demographics, and emerging economies in countries such as India and China are anticipated to lead to the growth of this region's market.
Furthermore, favorable reimbursement regulations and improved healthcare infrastructure are propelling apheresis equipment sales in India, China, and Japan. In addition, other factors, such as the introduction of advanced variations with automated interface systems, screen navigation, and graphical user interface displays, and increased research and development spending, are projected to boost the market in the future years.
A few of the notable companies playing a leading role in the Asia-pacific apheresis market profiled in the report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region